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Abstract
Objectives—To prospectively assess the value of serum total bilirubin (TB) within 3 months of 
hepatoportoenterostomy (HPE) in infants with biliary atresia (BA) as a biomarker predictive of 
clinical sequelae of liver disease in the first two years of life.
Study design—Infants with BA undergoing HPE between June 2004-January 2011 were 
enrolled in a prospective, multicenter study. Complications were monitored until 2 years of age or 
the earliest of liver transplant (LT), death, or study withdrawal. TB below 2 mg/dL (34.2 μM) at 
any time in the first 3 months (TB<2.0, all others = TB≥2) after HPE was examined as a 
biomarker, using Kaplan-Meier survival and logistic regression.
Results—Fifty percent (68/137) of infants had TB<2.0 in the first 3 months after HPE. 
Transplant-free survival at 2 years was significantly higher in the TB<2.0 group vs. TB≥2 (86% 
vs. 20%, p<0.0001). Infants with TB≥2 had diminished weight gain (p<0.0001), greater 
probability of developing ascites (OR 6.4, 95% CI 2.9–14.1, p<0.0001), hypoalbuminemia (OR 
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7.6, 95% CI 3.2–17.7, p< 0.0001), coagulopathy (OR 10.8, 95% CI 3.1–38.2, p=0.0002), LT (OR 
12.4, 95% CI 5.3–28.7, p<0.0001), or LT or death (OR 16.8, 95% CI 7.2–39.2, p<0.0001).
Conclusions—Infants whose TB does not fall below 2.0 mg/dL within 3 months of HPE were at 
high risk for early disease progression, suggesting they should be considered for LT in a timely 
fashion. Interventions increasing the likelihood of achieving TB <2.0 mg/dL within 3 months of 
HPE may enhance early outcomes.
Keywords
cholestasis; bile; liver; infant; health outcomes; transplant; cirrhosis; ascites; varices
Although biliary atresia (BA) is a rare disorder occurring between 1 in 8,000 and 1 in 18,000 
live births, nearly half of affected children will require liver transplantation (LT) within the 
first two years of life. An additional 20%–30% will require LT in childhood and 
adolescence. Consequently, BA is the leading indication for LT in childhood, accounting for 
nearly 35% of pediatric LT (based upon OPTN data as of February 16, 2015, http://
optn.transplant.hrsa.gov/converge/data/). The underlying cause(s) and mechanisms of 
progression of this fibro-inflammatory obliterative cholangiopathy are unknown. The sole 
intervention that has been shown to affect survival with native liver is the 
hepatoportoenterostomy (HPE), commonly referred to as the Kasai procedure since it was 
first described by Morio Kasai 1. In cases where the HPE is ineffective in restoring bile flow, 
there is rapid progression to biliary cirrhosis, liver failure, and death by 2–3 years of age 2. 
Though LT is an excellent option to restore health, prediction of the need for and 
determining the optimal timing of LT are challenging. Predictors of outcomes in BA have 
been identified largely through single center studies or retrospective multicenter 
analyses 3–20. Despite BA becoming the focus of increased research activity in the past 
decade, prospective multicenter studies of clinical outcomes are limited.
This study reports findings of the Prospective Database of Infants with Cholestasis (PROBE) 
study undertaken by the 16 member institutions and investigators of the National Institutes 
of Diabetes, Digestive and Kidney Diseases (NIDDK of the NIH)-supported Childhood 
Liver Disease Research Network (ChiLDReN; formerly the Biliary Atresia Research 
Consortium, BARC). PROBE was designed to acquire longitudinal, prospective clinical and 
laboratory data in a standardized fashion at defined time points to enable definitive studies of 
natural history of cholestatic liver diseases in infants and early childhood. Here, we focus on 
the analysis of the outcomes of children with BA over the first 24 months of life and the 
laboratory and clinical markers that predict these near-term outcomes. We hypothesized that 
serum levels of total bilirubin (TB) in the first 3 months after HPE (as an indicator of 
successful bile drainage post-HPE) would be predictive of 2 year outcomes in children with 
BA.
Methods
Study participants included subjects enrolled in PROBE (Clinicaltrials.gov: NCT00061828), 
more than two years before the data cutoff date (ie, who had the potential for at least 2 years 
of follow-up). Informed consent was obtained from parents or guardians and the protocol 
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was carried out under IRB approval. Inclusion criteria for enrollment in PROBE included 
presentation prior to 180 days of age with cholestasis defined as serum direct or conjugated 
bilirubin greater than or equal to 2.0 mg/dL and greater than 20% of TB. Infants who had 
undergone previous hepatobiliary surgery with dissection or excision of biliary tissue before 
presentation at a ChiLDReN site were not eligible for PROBE. The study population for this 
report was further restricted to subjects with BA who underwent HPE. After September 1, 
2005, PROBE participants with BA who underwent HPE were eligible to be co-enrolled in a 
prospective, randomized double-blinded, placebo-controlled trial of corticosteroid therapy 
after HPE for BA (START; Clinicaltrials.gov: NCT 00294684). Participants co-enrolled in 
START (n=135) were excluded from this analysis because they were the focus of a separate 
report 21. Corticosteroids were not typically employed as adjunctive therapy to HPE outside 
of START.
Data prospectively collected by study research coordinators and clinical investigators were 
entered into a centralized database at the data coordinating center. Baseline data included 
demographics, medical and family history, and laboratory studies. Follow-up visits for data 
collection occurred at 1, 2, 3, and 6 months after HPE and at 12, 18, and 24 months of age.
Data analyses
Descriptive data were summarized as the mean and standard deviation (SD) for continuous 
variables and as percentages for categorical variables. In addition to the descriptive analysis 
of baseline variables, we evaluated the fidelity of TB as a marker of clinical outcomes at 3 
months up to 2 years of age following surgical drainage. Outcomes of interest included 
survival with native liver and complications of advancing liver disease, including 
manifestations of portal hypertension. Response to HPE was dichotomized into two groups 
based upon TB levels in the first 3 months after HPE. TB < 2.0 mg/dL (TB<2) was defined 
by any TB less than 2.0 mg/dL (34.2 μM) within the first 3 months post HPE, and TB≥2.0 
was defined as never achieving a TB less than 2.0 mg/dL in the first 3 months post-HPE.
Logistic regression was used to model the probability that a specific clinical event occurred 
at least once in the period beginning 3 months after HPE as a function of the TB dichotomy 
described above. The clinical end points of interest were development of ascites (deemed 
clinically significant and/or requiring ongoing diuretic therapy), variceal hemorrhage 
(gastrointestinal bleed confirmed on endoscopy), thrombocytopenia (platelet count < 
150,000 × 109/L), splenomegaly (spleen palpable more than 2 cm below the costal margin), 
hypoalbuminemia (serum albumin < 3.0 gm/dL), hyponatremia (serum sodium < 130 
mmol/L), coagulopathy (INR > 1.5), weight-for-age z-scores (failure to thrive defined as a z-
score < −2.5), height-for-age z-scores, mid-arm circumference z-scores, receiving a liver 
transplant, and death. The number and proportion for each TB group is reported, as well as 
an odds ratio, p-value, and 95% confidence interval. In addition, 2-year Kaplan-Meier 
survival curves were generated to examine the time course for these clinical outcomes for 
each TB group, starting at HPE. To determine the relationship of successful HPE drainage in 
the first 3 months with each outcome, in all the above analyses, participants who had 
experienced the outcome of interest or underwent transplant or died before 3 months after 
HPE were excluded from the analysis cohort. An event was defined as the first occurrence of 
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the clinical end point, with subjects censored at the earlier of transplant or death (except for 
the transplant or death analysis, where this would be considered the end point), loss to 
follow-up, or the end of the data collection period (January 1, 2013).
To compare the mean time trajectories of weight z-score and height z-score between the two 
TB groups, we used a joint model of longitudinal and survival data with penalized B-
splines 22, 23 to adjust for potential bias due to informative dropout caused by liver 
transplant 24. In addition, the same method was used to estimate the mean trajectories of TB 
in the two TB groups. This joint model corrects the bias caused by informative dropout in a 
conventional longitudinal model. The ROC AUC (area under the receiver operating 
characteristic curve) for logistic models predicting transplant-free survival using different 
TB thresholds at 3 months and 6 months post-HPE was calculated and compared 25.
All analyses were performed using SAS/STAT (SAS Institute Inc. 2008. SAS/STAT® 9.2 
User’s Guide. Cary, NC: SAS Institute Inc.).
Results
Three hundred and twenty-four infants with BA were enrolled in PROBE between June 1, 
2004, and January 1, 2011, of whom 187 were excluded from this analysis. One hundred and 
thirty-five were also enrolled in START, 4 had laparoscopic HPE, 27 did not have an HPE 
procedure, and 21 had reasons prior to the 3 month post-HPE time point which precluded 
their inclusion in the final analysis (1 death, 3 LT, 7 withdrawn or lost to follow up from the 
study, and 10 without TB measurements). One hundred and thirty-seven participants (70 
female) were available for analysis (82 white, 18 black, 12 Asian, 18 other race, and 4 
unknown; 33 Hispanic). HPE was performed at a mean of 58.5 days (SD 20.7 days). 
Fourteen had biliary atresia splenic malformation as defined by the presence of polysplenia 
or asplenia.
Survival with Native Liver
At age 2 years, 73 children were alive with their native livers, 53 had undergone LT, 9 died 
without LT, and 2 were lost to follow up. The TB < 2.0 mg/dL by 3 months post-HPE 
criteria were met by 68 (50%) infants and 56 (82%) of these infants were alive with native 
liver at age 2 years (Table). In contrast, in the 69 infants in the TB≥2 group, only 15 (22%) 
were alive with native liver at age 2 years. Clinical complications of advancing liver disease 
were observed in 11 of these 15 participants (ascites – 1, splenomegaly – 5, 
hypoalbuminemia – 3, thrombocytopenia – 8, failure to thrive – 2, multiple complications - 
9). By both logistic regression and log-rank test, death or LT within the first 2 years of life 
was more likely for those TB≥2 infants compared with TB<2.0 infants (Table and Figure 1).
The ROC AUC for the logistic model using a TB threshold of 2.0 mg/dL at 3 months post-
HPE was 0.80, indicating a good predictive power for assessing the probability of LT or 
death prior to transplant. We also evaluated the impact of using a few different TB values 
with an alternative threshold (1.5 mg/dL, 25.6 μM) and/or using TB values within the first 6 
months after HPE for predicting outcomes. Using a TB threshold of 2.0 mg/dL at 6 months 
post-HPE did not improve the ROC significantly (AUC=0.82, p=0.412 compared with TB < 
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2.0 mg/dl at 3 months). Using a TB threshold of 1.5 mg/dL at 3 months (AUC=0.82, p = 
0.443) also yielded similar results. Finally, using a TB threshold of 1.5 mg/dL at 6 months 
post-HPE (AUC=0.87) did significantly improve the ROC (p=0.012).
Manifestations of Progressive Liver Disease
Logistic regression analyses were performed for the selected end points in the first 2 years of 
life related to the TB status in the first 3 months after HPE. TB≥2 infants were significantly 
more likely to subsequently develop failure to thrive (wt z-score < −2.5), hypoalbuminemia, 
coagulopathy, and ascites (Table). By Kaplan-Meier analysis, the likelihood of specific 
adverse clinical events in the first 2 years of life was significantly less in TB<2.0 infants, 
including thrombocytopenia, hypoalbuminemia, ascites, and coagulopathy (Figure 1). 
Notably, the development of hyponatremia (3.7% overall) and variceal hemorrhage (6.6% 
overall) were uncommon events in this cohort and thus there was insufficient power for 
detecting statistically significant differences between the two TB groups. Screening 
endoscopy was not routine (4/subjects screened) so the presence of varices could not be used 
as a marker of portal hypertension.
Growth
Figure 2 shows the estimated growth curves of weight z-score and height z-score for TB<2.0 
infants compared with TB≥2 infants. Although the weight z-score in both groups of children 
decreased after HPE, children with TB<2.0 started to recover soon (about 1 month) after 
HPE and their mean weight z-score was near 0.0 at 2 years of age. In contrast, the mean 
weight z-score in children with TB≥2 dropped until about 3 months and remained 
approximately −1.5 through 2 years of age. The trajectories of weight z-scores of the two 
groups were significantly different from each other (p<0.0001). The length z-score trajectory 
also differed significantly between the two groups (p=0.025). Length z-score in infants with 
TB< 2.0 improved linearly after HPE. In contrast, mean length z-score in infants with TB≥2 
dropped until 6 months after HPE and started to improve after that, primarily because of 
censoring of those who died or underwent LT.
Stability of TB status after HPE
To further investigate the utility of TB in the first 3 months after HPE as a predictive 
biomarker of 2-year clinical outcome, we analyzed all repeated measurements of TB up to 2 
years of age (the duration of the study) (Figure 3; available at www.jpeds.com). Of the 68 
infants with TB < 2.0 mg/dL within the first 3 months, TB remained <2.0 mg/dL in 62 
(91.2%) up to 2 years of age, and of the 69 with TB above 2.0 mg/dL, TB remained ≥2.0 
mg/dL in 52 (75.4%) (Figure 3, A and B). The incidence of significant events correlated 
with TB status over the first 2 years of life. In the 52 subjects who never had a TB <2.0 
mg/dL after HPE, 48 had an event (92%). In contrast, in the 62 subjects who persistently 
maintained at TB < 2.0 mg/dL once attained, only ten underwent LT (eight) or died (two) 
within the first 2 years of life. In 23 infants, the TB crossed the 2.0 mg/dL threshold after 3 
months post-HPE (Figure 3, C). Six in the TB< 2.0 group subsequently had TB ≥ 2.0 mg/dL 
prior to 2 years of age; two of these participants underwent LT prior to 2 years of age. 
Seventeen in the TB≥2 group subsequently had a TB <2.0 mg/dl. Four of these 17 
Shneider et al. Page 6
J Pediatr. Author manuscript; available in PMC 2017 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
underwent LT prior to 2 years of age. Thus, those with fluctuating TB levels had a course 
more consistent with the TB<2.0 group.
Discussion
Accurate early prediction of poor prognosis after HPE for BA permits focused anticipatory 
guidance and monitoring related to potential complications of advancing liver disease, 
implementation of prophylactic therapies and nutritional support, and early consideration of 
liver transplantation, especially living donor transplantation. The general importance of 
restitution of bile flow after HPE has been known for decades, although precision about this 
issue has not been the subject of detailed prospective investigation 26, 27. In this large, 
prospective, and multicenter study, the simple parameter of TB within the first 3 months 
after HPE performs very well to predict outcome in the first 2 years of life. TB ≥ 2.0 mg/dL 
by 3 months after HPE identifies the large majority of children who will die or require LT by 
2 years of age and also predicts those who will develop early complications of chronic liver 
disease. These findings prospectively validate the results of our prior retrospective 
analysis 11. The current study simplifies the predictor of outcome using a dichotomization 
relative to a TB of 2.0 mg/dL.
This multicenter series prospectively collected data on a contemporary group of children 
from the time of diagnosis of BA in a standardized manner, thereby allowing careful 
characterization of outcomes linked to early events. Single center studies have required 10 to 
20 years to accumulate similar types of data 6, 28. The enrollment of this cohort in 7 years 
with a 2-year outcome minimizes era effects in the interpretation of the data and the 
complications. The largest outcome study in France included patients diagnosed over more 
than a 20-year time interval 13, 14, 29, 30, and studies in Finland, the United Kingdom, and the 
Netherlands accumulated patients over 10 to 20 years 13, 14, 29, 30. Unlike retrospective 
analyses, clinical events in this study were defined a priori by agreed upon criteria and were 
prospectively identified, thus enhancing accurate collection of complications and 
minimizing bias. Previous studies have typically reported normalization of TB (< 20μM) at 6 
months after HPE and have correlated this with survival with native liver. Those studies have 
not systematically assessed the predictive value of this finding relative to complications of 
progressive liver disease nor variation of TB measurements over time.
Liver transplantation can be a problematic end point, when TB is used as a biomarker of 
outcome as the timing of liver transplantation is somewhat subjective. Some clinicians feel 
that LT is indicated in infants with an unsuccessful HPE, given the poor prognosis associated 
with lack of bile drainage in BA and thus TB could be, a self-fulfilling prophecy, strongly 
correlated with LT. 31,32 One of the major strengths of the current study is that it 
demonstrates that TB ≥ 2.0 mg/dL predicts other adverse clinical outcomes related to 
advancing liver disease, such as growth failure, ascites, or hypoalbuminemia, thereby 
supporting the potential role of TB as an important biomarker of 2-year outcome.
Despite the frequent findings of features of portal hypertension in this entire cohort, variceal 
hemorrhage was uncommon in either TB group by 2 years of age, occurring in only 6.6% of 
participants. Moreover, variceal hemorrhage episodes were not fatal in any of the infants 
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with BA in this series. This is in contrast to recent reports highlighting a relatively high 
frequency of esophageal varices in infants with BA and the potential need for primary 
endoscopic prophylaxis of varices in infants with BA 33, 34. It is possible that the use of early 
LT may have altered the natural history of GI bleeding in these patients compared with other 
studies. In a program using primary prophylaxis of varices, a total serum bilirubin > 40 μM 
at 6 months after HPE predicted subsequent presence of and bleeding from esophageal 
varices, which supports the importance of bile flow as a predictor of progressive liver 
disease 35.
Total bilirubin measurement within the first 3 months of HPE is a stable predictive 
biomarker. In those infants with fluctuating levels clinical outcomes were more consistent 
with the low TB group. Somewhat improved prediction of survival with native liver can be 
achieved using a TB cut-off of 1.5 mg/dL over the 6 months after HPE. However, waiting 
until 6 months after HPE may diminish the ability to preempt the development of serious 
complications (Figure 1). In practice, it would be reasonable to consider LT evaluation in 
infants with BA whose TB does not fall below 2.0 mg/dL in the first 3 months after HPE 
(Figure 4). LT might be reconsidered in the small number of these infants, whose TB 
subsequently falls below 1.5 mg/dL in the first 6 months after HPE.
In conclusion, we have demonstrated in a prospective, multicenter study of a large cohort of 
infants with BA that failure to achieve a TB of < 2.0 mg/dL in the first 3 months after HPE is 
associated with a high risk of complications of progressive liver disease and subsequent 
death or need for LT in the first 2 years of life. Conversely, infants who achieve at least one 
TB of < 2.0 mg/dL within 3 months of HPE have a moderate risk of developing features of 
portal hypertension but have a significantly reduced risk of complications of progressive 
liver disease, LT, or death events by 2 years of age. The odds ratio of death or transplant 
within the first 2 years of life for those with TB ≥ 2.0 versus < 2.0 mg/dL in the first 3 month 
post-HPE was 16.8. We propose that TB should be consistently determined in the first 6 
months following HPE and results should be interpreted using a threshold of 2.0 mg/dL 
(34.2 μM; Figure 4). Families of those infants whose TB does not fall below 2 mg/dL in the 
first 3 months after HPE should receive enhanced anticipatory guidance about complications 
of end-stage liver disease. Intensive nutritional monitoring and interventions may be 
warranted, especially in light of the high risk of failure to thrive and fat soluble vitamin 
insufficiencies in infants with poor bile flow after HPE 37, 38. In addition, these infants might 
be considered for relatively pre-emptive living donor LT potentially avoiding long term 
sequelae and potential mortality associated with advancing disease. TB in the first 3 months 
is an appropriate biomarker and end point for future clinical trials of near-term outcomes in 
BA. Ongoing studies from ChiLDReN will further delineate the variables that impact TB 
within the 3 three months after HPE.
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Figure 1. 
Kaplan-Meier estimate and its 95% confidence interval for onset of specific clinical 
outcomes beginning 3 months after HPE in children who did (blue dashed lines) or who did 
not achieve a TB < 2.0 mg/dL (red solid lines) in the first 3 months. Curves represent 
probability of remaining free of the clinical outcome. Rapid and clear differences were 
observed for thrombocytopenia (A), hypoalbuminemia (B), ascites (C), and death or liver 
transplant (D). Time zero is the time of the HPE. Secondary lines surrounding primary data 
lines indicate 95% confidence limits.
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Figure 2. 
Growth curves plotting weight z-score (panel A) and length z-score (panel B) vs. time since 
HPE. Blue solid lines (subjects who achieved a TB < 2.0 mg/dL in the first 3 months after 
HPE) and red dashed lines (subjects who did not achieve a TB < 2.0 mg/dL) represent the 
average value over time and its 95% confidence intervals. The apparent improved length z-
score after 1 year (dashed line) was due to censoring of those who died or underwent LT.
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Figure 3. 
online. Trends in TB over time for children who achieved a TB < 2.0 mg/dL in the first 3 
months after HPE (panel A) compared to those who did not (panel B). Solid bold lines 
represent the average value over time (dotted lines 95% confidence intervals). Gray open 
circles and lines in both panels represent bilirubin trajectories for individual subjects. 
Horizontal dashed line indicates a TB of 2.0 mg/dL. BA infants generally maintain their 
group assignment defined at 3 months post-HPE. The trajectories of those that changed 
status after 3 months post-HPE are seen in panel C.
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Figure 4. 
If the TB is found to be less than 2 mg/dL (34.2 μM) in the first three months, routine 
follow-up for BA is recommended. If not, heightened nutritional monitoring and 
supplementation, anticipatory guidance for potential complications of advanced liver disease 
and liver transplant evaluation is recommended. If in the subsequent three months the TB is 
found to be less than 1.5 mg/dL, candidacy for liver transplantation should be reassessed in 
the context of the clinical status of the infant.
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